Search clinical trials for: Faropenem medoxomil

Total 338 results

Replidyne

Completed

A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media

Otitis Media

Costa Rica, Israel
Replidyne
INC Research Limited

Terminated

A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis

Chronic Bronchitis

United States
University of Chicago
Takeda

Completed

Effect of Azilsartan on Aldosterone in Postmenopausal Females

Hypertension

United States
Lee's Pharmaceutical Limited

Completed

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Hypertension

China
Daiichi Sankyo, Inc.

Completed

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Hypertension

United States, Colombia, Argentina, Peru, Brazil, Kenya, Chile, South Africa, India, Zambia, Uganda
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Essential Hypertension

China
Takeda

Completed

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Safety

Ukraine, Germany, Poland, Bulgaria, Netherlands, Lithuania, Slovakia, Latvia
TASK Applied Science
GlaxoSmithKline; Research Center Borstel; Eduardo Mondlane University; Barcelona...

Completed

Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis

Pulmonary Tuberculosis

South Africa
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Chile, Mexico
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Essential Hypertension

United States, Canada
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Mexico, Argentina
Celltrion Pharm, Inc.

Completed

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Essential Hypertension

Korea, Republic of
Shenzhen People's Hospital

Recruiting

s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension

Essential Hypertension

China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia

Community Acquired Pneumonia

China
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Central South University

Completed

Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers

Drug Interaction of Olmesartan in Healthy Chinese Volunteers

China
Takeda

Completed

International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

Hypertension

Russian Federation, Kazakhstan
Takeda

Completed

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Type 2 Diabetes Mellitus | Essential Hypertension

Taiwan, Thailand, China
Qilu Pharmaceutical Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)

Healthy

China
Arbor Pharmaceuticals, Inc.

Completed

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Hypertension

United States, Brazil, Turkey, Poland, Mexico, Colombia, Italy, Argentina, Bulgaria, Hungary, South Africa, Ukraine
Mahidol University

Completed

Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients

Sepsis | Critical Illness | Septic Shock | Morality | Pharmacokinetic | Carbapenem | Pharmacodynamic | Clinical Outcome | Organ Failure, Multiple

Thailand
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Takeda

Completed

Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

Essential Hypertension

Netherlands, Austria, Germany, Poland, United Kingdom
Takeda

Terminated

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

Hypertension

United States, United Kingdom
Tohoku University

Completed

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT)

Chronic Heart Failure

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy

Diabetic Nephropathy | Chronic Glomerulonephritis

Japan
Daiichi Sankyo, Inc.

Completed

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

Hypertension

United States
Austin Health

Completed

A Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Unit (ICU) Patients (MERO001)

Sepsis

Australia
Unity Health Toronto
Sunnybrook Health Sciences Centre; University of Toronto

Terminated

Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients

Cystic Fibrosis Pulmonary Exacerbation

Canada
Oslo University Hospital

Recruiting

A Pilot Study for Optimizing Meropenem Administration in the ICU (MER6)

Drug Effect

Norway
Xinhua Hospital, Shanghai Jiao Tong University...

Completed

Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients

Sepsis

China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Hypertension | Metabolic Syndrome

Italy, Belgium, Germany
Virginia Polytechnic Institute and State University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Angiotensin II Blockade and Inflammation in Obesity (ARB)

Hypertension | Overweight | Prehypertension | Obese
Research Institute for Complex Problems of Cardiovascular...

Completed

Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus. (AcADEME)

Diabetes Mellitus | Arterial Hypertension | Stable Chronic Angina

Russian Federation
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo, Inc.

Completed

Olmesartan Pediatric Pharmacokinetic (PK) Study

Hypertension

United States
Daiichi Sankyo, Inc.

Completed

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Atherosclerosis
Daiichi Sankyo Co., Ltd.

Completed

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria

Japan, China
Pfizer

Completed

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Hypertension
Qingtao Zhou

Completed

Meropenem Dosage Strategy Based on PPK Model

Lower Respiratory Tract Infection

China
Takeda

Completed

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Hypertension

United States, Mexico, Chile, Peru
Daiichi Sankyo, Inc.
Shanghai Sankyo Pharmaceuticals Co., Ltd.

Completed

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

China
Mansoura University

Completed

Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis (BVPIMNBLOS)

Late Onset Neonatal Sepsis
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Hypertension

United States
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis | Pancreatic Exocrine Insufficiency

United States
Takeda

Completed

Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension

Hypertension

Korea, Republic of
Daiichi Sankyo Co., Ltd.

Completed

Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension

Hypertension

Japan
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia

Community Acquired Pneumonia

China
Joseph Kuti
Thrasher Research Fund

Completed

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

Pneumonia | Cystic Fibrosis | Pseudomonas Aeruginosa Infection

United States

3

Subscribe